Ingrezza (valbenazine) is solitary US Food and Medication Organization (FDA) supported vesicular monoamine carrier 2 (VMAT2) inhibitor showed for the treatment of grown-ups with Tardive dyskinesia (TD).
The medication was found and created by Neurocrine Biosciences, which got advancement treatment assignment from the FDA in 2014.
Neurocrine's new medication application (NDA) for Ingrezza was...
English 
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek